Sodium/glucose cotransporter 2 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sodium/glucose cotransporter 2" in English language version.

refsWebsite

Global rank English rank

13nih.gov

4^th place

7doi.org

2^nd place

2ensembl.org

1,626^th place

1,007^th place

1fda.gov

447^th place

338^th place

1jwatch.org

low place

1diabetes.co.uk

low place

1elsevier.com

610^th place

704^th place

diabetes.co.uk

"SGLT2 Inhibitors (Gliflozins)". Diabetes.co.uk. Retrieved 2015-05-19.

doi.org

Wells RG, Mohandas TK, Hediger MA (September 1993). "Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere". Genomics. 17 (3): 787–789. doi:10.1006/geno.1993.1411. PMID 8244402.
Bonora BM, Avogaro A, Fadini GP (2020). "Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity. 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
Vallon V, Thomson SC (2012). "Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney". Annual Review of Physiology. 74: 351–375. doi:10.1146/annurev-physiol-020911-153333. PMC 3807782. PMID 22335797.
Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD (November 2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J (2017). "Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma". Endocrinology, Diabetes & Metabolism Case Reports. 2017. doi:10.1530/EDM-17-0081. PMC 5592704. PMID 28924481.
Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, et al. (March 2006). "Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting". Kidney International. 69 (5): 852–855. doi:10.1038/sj.ki.5000194. PMID 16518345.
Lemonjava I, Gudushauri N, Tskhakaia I, Martinez Manzano JM, Azmaiparashvili Z (2024). "Impact of Sglt2 Inhibitors on Mortality in Pulmonary Arterial Hypertension: Exploring the Association". Chest. 166 (4): A5793. doi:10.1016/j.chest.2024.06.3435.

elsevier.com

linkinghub.elsevier.com

Lemonjava I, Gudushauri N, Tskhakaia I, Martinez Manzano JM, Azmaiparashvili Z (2024). "Impact of Sglt2 Inhibitors on Mortality in Pulmonary Arterial Hypertension: Exploring the Association". Chest. 166 (4): A5793. doi:10.1016/j.chest.2024.06.3435.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000140675 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000030781 – Ensembl, May 2017

fda.gov

"FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood". Food and Drug Administration, USA. 2015-05-15.

jwatch.org

"SGLT2 Inhibitors Associated with Fournier Gangrene". Jwatch.org. Retrieved 2019-05-06.

nih.gov

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: solute carrier family 5 (sodium/glucose cotransporter)".
Bonora BM, Avogaro A, Fadini GP (2020). "Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity. 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
Vallon V, Thomson SC (2012). "Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney". Annual Review of Physiology. 74: 351–375. doi:10.1146/annurev-physiol-020911-153333. PMC 3807782. PMID 22335797.
Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD (November 2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J (2017). "Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma". Endocrinology, Diabetes & Metabolism Case Reports. 2017. doi:10.1530/EDM-17-0081. PMC 5592704. PMID 28924481.

pubmed.ncbi.nlm.nih.gov

Wells RG, Mohandas TK, Hediger MA (September 1993). "Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere". Genomics. 17 (3): 787–789. doi:10.1006/geno.1993.1411. PMID 8244402.
Bonora BM, Avogaro A, Fadini GP (2020). "Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity. 13: 161–174. doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362.
Vallon V, Thomson SC (2012). "Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney". Annual Review of Physiology. 74: 351–375. doi:10.1146/annurev-physiol-020911-153333. PMC 3807782. PMID 22335797.
Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD (November 2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416.
Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J (2017). "Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma". Endocrinology, Diabetes & Metabolism Case Reports. 2017. doi:10.1530/EDM-17-0081. PMC 5592704. PMID 28924481.
Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, et al. (March 2006). "Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting". Kidney International. 69 (5): 852–855. doi:10.1038/sj.ki.5000194. PMID 16518345.